Aurigene Oncology Limited, a wholly owned subsidiary of Dr Reddy’s Laboratories, on December 16 announced that it will stop the clinical development of AUR-101, an oral drug for moderate to severe psoriasis, in the US.
Aurigene Discovery Technologies Limited rebrands to Aurigene Oncology Limited with sharpened focus on cancer care
Aurigene inks drug discovery, development pact with US-based EQRx
Dr Reddy's Laboratories on Thursday said its subsidiary has inked a pact with US-based Olema Pharmaceuticals Inc to research, develop and commercialise novel small molecule inhibitors of an undisclosed oncology target. Olema and Aurigene Discovery Technologies, a wholly-owned unit of Dr Reddy's Laboratories, have inked an exclusive global licence agreement in this regard.
Exelixis (NASDAQ:EXEL) and Aurigene Discovery Technologies Limited disclosed new preclinical data showing that AUR102, selective and orally bioavailable covalent inhibitor of cyclin-dependent kinase 7 (CDK7), has potent anti-tumor activity in a large panel of cancer cell lines with induction of cell death in cell lines derived from multiple cancer types.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Aurigene Discovery Technologies Limited (Aurigene) today disclosed new preclinical data showing that AUR102 has potent anti-tumor activity in a large panel of cancer cell lines. AUR102 is a potent, selective, and orally bioavailable covalent inhibitor of cyclin-dependent kinase 7 (CDK7), which is an important regulator of the cellular transcriptional and cell cycle machinery. Exelixis has an exclusive option for AUR102 under its July 2019 exclusive collaboration, option and license agreement with Aurigene. The new data will be presented in a poster (Abstract 170) at the 32nd EORTC-NCI-AACR (ENA) Symposium, which is being held virtually on October 24-25, 2020.